A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers*, D. Craig Wright, Joan Brisker, Ann Williams, Graham Hatch, Dolores Gavier-Widén, Graham Hall, Philip D. Marsh, R. Glyn Hewinson

*Awdur cyfatebol y gwaith hwn

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

35 Dyfyniadau (Scopus)

Crynodeb

The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

Iaith wreiddiolSaesneg
Tudalennau (o-i)1063-1071
Nifer y tudalennau9
CyfnodolynVaccine
Cyfrol22
Rhif cyhoeddi8
Dyddiad ar-lein cynnar14 Hyd 2003
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - 25 Chwef 2004

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn